Purpose. To report the outcome of 37 patients with metastatic osteosarcoma entered into a large randomized trial (EOI 80831/MRC B002) comparing two different regimens of chemotherapy in patients with osteosarcoma.
Introduction
The most common type of osteosarcoma is the so-called 'classical variety', which occurs in the limbs of children and young adults. Until the introduction of intensive adjuvant chemotherapy, the outlook after surgery alone was extremely poor but with modern multi-agent chemotherapy, 5 -year survival figures for non-metastatic cases range between 40 and 800/0. 2 Unfortunately, between 15 and 20% of patients with osteosarcoma will present with clinically detectable metastases, a proportion that has increased with sophisticated methods of detection, such as computed tomography (CT) scanning of the lungs. It is common to treat these patients aggressively with intensive multi-agent chemotherapy, followed by resection of metastases particularly if these are confined to the lung, but results are poor. 3'4 As determined by measurable objective response, chemotherapy has always produced rather unim- short intensive cytotoxic regimens were to be compared for response and toxicity. Treatment in one arm was an intensive doxorubicin/cisplatin (DOX/ DDP) regimen, and in the other arm the same drugs were given alternately with high-dose methotrexate (HDMTX). These were chosen because the role of HDMTX in patients treated with other drugs known to be highly effective in osteosarcoma was controversial. The study recruited patients rapidly, and the manageability and early efficacy of the regimens, judged by clinical response, was such that the study was expanded to a formal phase III trial in which survival was the main endpoint. Results of this protocol in non-metastatic patients who received neo-adjuvant and adjuvant chemotherapy have been reported previously. 6 As this protocol was originally designed to evaluate response and toxicity, patients presenting with initial metastases, axial or locally recurrent tumors were also eligible for the study, and this report describes the outcome for the patients with metastatic disease.
Patients and methods

Study population
Patients with biopsy-proven high-grade osteosarcoma, who were aged 40 years or younger, were In this subgroup of patients with metastatic tumors, the objectives were to assess clinical and radiological response and survival. Toxicity was described in the previous report 6 and was not quantitatively different in this group of patients. The method of randomization has been described previously. 6 The treatments were designed to be of equal duration so that the planned dose intensities of The clinical characteristics of the metastatic cases are shown in Table 1 . Twenty-four cases were randomized to receive the two-drug regimen and 13 to receive the three-drug regimen. Allowing for small numbers and a chance excess of cases in the twodrug arm, there were no major differences in characteristics such as age, sex, primary site and performance status according to treatment arm. The median age was 18 years. Elevated levels of serum AP at presentation were observed more frequently (96% vs 42%) in the two-drug arm. In 21/24 patients in the two-drug arm and 11/13 patients in the three-drug arm, metastases were present concurrent with the primary tumor.
Eleven patients (46%) completed the full course of six treatment cycles on the two-drug arm. Progression of disease occurred in nine patients after one (one patient), two (one patient), three (four patients), four (two patients) and five (one patient) cycles. Two patients refused treatment after three and five cycles, and two patients stopped after five cycles because of liver function abnormalities and impaired renal function, respectively. In contrast, on the three-drug regimen, only two patients failed to complete the full course of four cycles of chemotherapy, terminating after one and three cycles, in both cases due to disease progression. Eight patients received the four planned cycles and three patients with responding disease received one to three additional cycles.
In the two-drug arm, 10/21 patients had resection of the primary tumor. In eight cases this was performed after three cycles of chemotherapy, as recommended in the protocol. In one patient, who did not receive the last two cycles because of progressive lung metastases, an above-knee amputation was performed 6 months later. A second patient, who achieved partial remission of both an upper humeral primary and metastases, underwent conservative surgery with insertion of a prosthesis after six cycles of chemotherapy. Five patients who had As far as metastases were concerned, in the twodrug arm, there was one CR and six PRs in 21 patients with radiologically evaluable metastases (overall response rate 33%, exact 95% CI 14-57%). In contrast, in the three-drug arm, there were three CRs and three PRs in 11 patients with evaluable metastases (overall response rate 55%, exact 95% CI 23-84%). The estimated difference in overall response rate is 21% (in favor of the three-drug arm) with a 95% exact CI ranging from 16% + 61%; the observed difference in overall response rate between therapeutic arms is not significant (Fisher exact two-sided test: p-0.28). When the response distribution was compared by the g 2 test for trend for ordered categorical variables, no significant difference was found between therapeutic arms (p 0.13)
The median follow-up is 8.6 years and 90% of patients have been followed for more than 6 years. Two-year survival figures are 36% and 69% for twoand three-drug arms, respectively, falling to 9% and 52% at 4 years (unadjusted hazard ratio 0.38, 95% CI 0.18-0.77; unadjusted log-rank test p= 0.008). However, when the comparison between the treatment arms was adjusted for the imbalance of AP levels (Fig. 1) , excluding one patient for whom AP was unknown, the difference in survival was no longer significant (hazard ratio 0.52, 95% CI 0.22-1.23; p 0.14). An 'intent to treat' analysis, including eligible and the two ineligible patients, provides similar hazard ratios and confidence limits.
Three patients are surviving long-term at 7.5, 10.9 and 11.6 years, all of whom were treated on the three-drug arm. In addition, these three patients presented with normal AP and small metastases in the lung as the only site of distant spread. Two of the three had their lung metastases resected. One patient treated on the three-drug arm, who had progressive lung and bone metastases, was lost to follow-up at 1.5 years. A second patient on the two-drug arm, with progression in lung and brain, was lost to follow-up at 1.3 years. All remaining patients have died.
Discussion
The most striking initial observation in this study was the significantly better survival for patient, with metastatic disease treated on the three-drug arm, and the fact that all three long-term survivors received this regimen. In addition, a higher proportion of patients in the three-drug arm (10/11 vs 10/21) initially considered to be operable went on to have definitive resection of the primary tumor. This apparent superiority of the three-drug arm is in marked contrast with the results of the adjuvant/neo-adjuvant component of the study 6 in which continuous disease-free survival was significantly better (p 0.02) for patients treated on the two-drug arm, with a similar trend for overall survival (p-0.10). Cancer Center 1975-1984 with five chemotherapy regimens (T4, T5, T7,  T10, T12) were alive at a minimum of 8 years follow-up. 4 In conclusion, it is likely that random bias in the population (small numbers, imbalance in size of the groups, uneven distribution of AP) accounts for the apparent difference in outcome favouring the threedrug treatment. More reliance can be placed on the finding that disease-free and overall survival in the adjuvant study 6 were better after two-drug treatment.
